DE60019814T2 - Pharmazeutische kombinationen enthaltend tegaserod und omeprazole und ihre verwendung zur behandlung gastrointestinaler krankheiten - Google Patents
Pharmazeutische kombinationen enthaltend tegaserod und omeprazole und ihre verwendung zur behandlung gastrointestinaler krankheiten Download PDFInfo
- Publication number
- DE60019814T2 DE60019814T2 DE60019814T DE60019814T DE60019814T2 DE 60019814 T2 DE60019814 T2 DE 60019814T2 DE 60019814 T DE60019814 T DE 60019814T DE 60019814 T DE60019814 T DE 60019814T DE 60019814 T2 DE60019814 T2 DE 60019814T2
- Authority
- DE
- Germany
- Prior art keywords
- tegaserod
- pharmaceutically acceptable
- omeprazole
- agent
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- IKBKZGMPCYNSLU-RGVLZGJSSA-N tegaserod Chemical compound C1=C(OC)C=C2C(/C=N/NC(=N)NCCCCC)=CNC2=C1 IKBKZGMPCYNSLU-RGVLZGJSSA-N 0.000 title claims description 32
- 229960002876 tegaserod Drugs 0.000 title claims description 31
- 238000011282 treatment Methods 0.000 title claims description 23
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 title claims description 18
- 229960000381 omeprazole Drugs 0.000 title claims description 18
- 208000018522 Gastrointestinal disease Diseases 0.000 title description 15
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000006186 oral dosage form Substances 0.000 claims description 2
- 239000000523 sample Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 description 43
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 34
- 208000002551 irritable bowel syndrome Diseases 0.000 description 17
- 230000028327 secretion Effects 0.000 description 16
- 230000035945 sensitivity Effects 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 201000006549 dyspepsia Diseases 0.000 description 12
- 239000003826 tablet Substances 0.000 description 12
- 230000005176 gastrointestinal motility Effects 0.000 description 10
- 208000024798 heartburn Diseases 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000002496 gastric effect Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 208000004998 Abdominal Pain Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000004899 motility Effects 0.000 description 7
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 7
- 229960000620 ranitidine Drugs 0.000 description 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 5
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 206010016766 flatulence Diseases 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 206010000087 Abdominal pain upper Diseases 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 206010059186 Early satiety Diseases 0.000 description 4
- 206010021518 Impaired gastric emptying Diseases 0.000 description 4
- 206010028813 Nausea Diseases 0.000 description 4
- 206010067171 Regurgitation Diseases 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 230000003628 erosive effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 230000008693 nausea Effects 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 229940076279 serotonin Drugs 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- 239000000654 additive Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 210000003238 esophagus Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 208000001288 gastroparesis Diseases 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical group OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 229940126409 proton pump inhibitor Drugs 0.000 description 3
- 239000000612 proton pump inhibitor Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000009935 visceral pain Diseases 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 206010051153 Diabetic gastroparesis Diseases 0.000 description 2
- 206010063655 Erosive oesophagitis Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010021639 Incontinence Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000020694 gallbladder disease Diseases 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 208000008384 ileus Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000000111 lower esophageal sphincter Anatomy 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 229940099076 maalox Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 230000009103 reabsorption Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000001148 spastic effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- IKBKZGMPCYNSLU-UHFFFAOYSA-N 1-[(5-methoxy-1H-indol-3-yl)methylideneamino]-2-pentylguanidine Chemical compound C1=C(OC)C=C2C(C=NNC(=N)NCCCCC)=CNC2=C1 IKBKZGMPCYNSLU-UHFFFAOYSA-N 0.000 description 1
- FWWOWPGPERBCNJ-UHFFFAOYSA-N 2-hydroxy-4-(2-hydroxyethoxy)-4-oxobutanoic acid Chemical group OCCOC(=O)CC(O)C(O)=O FWWOWPGPERBCNJ-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010017943 Gastrointestinal conditions Diseases 0.000 description 1
- 206010017999 Gastrointestinal pain Diseases 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 244000141359 Malus pumila Species 0.000 description 1
- 206010068871 Myotonic dystrophy Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000008993 bowel inflammation Effects 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 206010013932 dyslexia Diseases 0.000 description 1
- -1 elixirs Substances 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 210000002322 enterochromaffin cell Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000011872 intimate mixture Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000333 poly(propyleneimine) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45838899A | 1999-12-10 | 1999-12-10 | |
| US458388 | 1999-12-10 | ||
| PCT/EP2000/012420 WO2001041748A2 (en) | 1999-12-10 | 2000-12-08 | Pharmaceutical combinations and their use in treating gastrointestinal disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60019814D1 DE60019814D1 (de) | 2005-06-02 |
| DE60019814T2 true DE60019814T2 (de) | 2006-03-02 |
Family
ID=23820591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60019814T Expired - Lifetime DE60019814T2 (de) | 1999-12-10 | 2000-12-08 | Pharmazeutische kombinationen enthaltend tegaserod und omeprazole und ihre verwendung zur behandlung gastrointestinaler krankheiten |
Country Status (30)
| Country | Link |
|---|---|
| EP (3) | EP1286668B1 (https=) |
| JP (1) | JP2003523324A (https=) |
| KR (1) | KR100765579B1 (https=) |
| CN (2) | CN1875966A (https=) |
| AR (1) | AR026916A1 (https=) |
| AT (1) | ATE293971T1 (https=) |
| AU (2) | AU778869B2 (https=) |
| BR (1) | BR0016275A (https=) |
| CA (1) | CA2388959A1 (https=) |
| CO (1) | CO5261535A1 (https=) |
| CZ (1) | CZ300690B6 (https=) |
| DE (1) | DE60019814T2 (https=) |
| DK (1) | DK1286668T3 (https=) |
| ES (1) | ES2240229T3 (https=) |
| HU (1) | HUP0301122A3 (https=) |
| IL (2) | IL149496A0 (https=) |
| MX (1) | MXPA02005695A (https=) |
| MY (1) | MY133423A (https=) |
| NO (1) | NO20022680L (https=) |
| NZ (2) | NZ531489A (https=) |
| PE (1) | PE20011030A1 (https=) |
| PL (1) | PL202201B1 (https=) |
| PT (1) | PT1286668E (https=) |
| RU (1) | RU2264215C2 (https=) |
| SG (1) | SG152025A1 (https=) |
| SK (1) | SK8062002A3 (https=) |
| TR (1) | TR200402293T2 (https=) |
| TW (1) | TWI263496B (https=) |
| WO (1) | WO2001041748A2 (https=) |
| ZA (1) | ZA200204493B (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001261606A1 (en) * | 2000-05-18 | 2001-11-26 | Glaxo Group Limited | Method for treating functional dyspepsia |
| GB0209481D0 (en) * | 2002-04-24 | 2002-06-05 | Novartis Ag | Organic compounds |
| NZ541009A (en) | 2003-01-13 | 2007-09-28 | Dynogen Pharmaceuticals Inc | Method of treating nausea, vomiting, retching or any combination thereof |
| GB0307440D0 (en) * | 2003-03-31 | 2003-05-07 | Novartis Ag | Organic compounds |
| JP2006528231A (ja) * | 2003-05-27 | 2006-12-14 | アルタナ ファルマ アクチエンゲゼルシャフト | プロトンポンプ阻害剤と胃腸運動性を変更する化合物との医薬品組合せ物 |
| US20050090554A1 (en) * | 2003-09-12 | 2005-04-28 | John Devane | Treatment of gastroparesis and nonulcer dyspepsia with GABAB agonists |
| US7820690B2 (en) | 2004-03-19 | 2010-10-26 | Solvay Pharmaceuticals Gmbh | Method of treating or inhibiting a non-digestive tract derived abdominal disorder associated with pain using a 5-HT, receptor antagonist |
| RU2007105346A (ru) * | 2004-07-14 | 2008-09-27 | Новартис АГ (CH) | Комбинация ингибиторов dpp-iv и соединений, модулирующих 5-нт3-и/или 5-нт4-рецепторы |
| MX2007009136A (es) * | 2005-01-31 | 2007-09-06 | Novartis Ag | Uso de agonista de 5-ht4 para tratar vacio gastrico retrasado que puede inducirse por un inhibidor de bomba de protones. |
| GB0506800D0 (en) * | 2005-04-04 | 2005-05-11 | Merck Sharp & Dohme | New uses |
| US8324192B2 (en) | 2005-11-12 | 2012-12-04 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| US8679545B2 (en) | 2005-11-12 | 2014-03-25 | The Regents Of The University Of California | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
| JP2009525269A (ja) | 2006-01-30 | 2009-07-09 | ユーロ−セルティーク エス．エイ． | カルシウムチャネルブロッカーとしての環状尿素化合物 |
| RU2008152196A (ru) * | 2006-06-15 | 2010-07-20 | Новартис АГ (CH) | Композиции, включающие тегасерод в отдельности или в комбинации с ингибитором протонного насоса, для лечения или профилактики повреждений желудочно-кишечного тракта |
| KR20090107088A (ko) | 2007-02-09 | 2009-10-12 | 트랜자임 파르마 인크 | 거대고리 그렐린 수용체 조절제 및 이의 사용 방법 |
| EP2214679B1 (en) | 2007-11-13 | 2019-03-27 | Meritage Pharma, Inc. | Corticosteroid compositions |
| US20090143343A1 (en) | 2007-11-13 | 2009-06-04 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| WO2018029474A2 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
| KR20260030924A (ko) | 2016-08-09 | 2026-03-06 | 키맵 리미티드 | 항-icos 항체 |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| EP3728314A1 (en) | 2017-12-19 | 2020-10-28 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
| US20220396623A1 (en) | 2021-05-18 | 2022-12-15 | Kymab Limited | Uses of anti-icos antibodies |
| GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
| US20250340641A1 (en) | 2022-05-18 | 2025-11-06 | Kymab Limited | Uses of anti-icos antibodies |
| FR3144752A1 (fr) | 2023-01-10 | 2024-07-12 | Song Huang | Utilisation de polysulfate de pentosane pour le traitement de la toux seche |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5362756A (en) * | 1989-02-20 | 1994-11-08 | Riviere Pierre J M | Use of fedotozine in the treatment of functional states of intestinal obstructions |
| HUT64023A (en) * | 1991-03-22 | 1993-11-29 | Sandoz Ag | Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds |
| EP0617620B1 (en) * | 1991-12-21 | 1998-09-09 | Smithkline Beecham Plc | Use of 5-ht4 - antagonists for the manufacture of a medicament for the treatment of urinary incontinence |
| GB9214184D0 (en) * | 1992-07-03 | 1992-08-12 | Smithkline Beecham Plc | Pharmaceuticals |
| DK0794184T3 (da) * | 1994-11-21 | 2001-07-30 | Dainippon Pharmaceutical Co | 6-Methoxy-1H-benzotriazol-5-carboxamidderivater, fremgangsmåde til fremstilling deraf og lægemidler indeholdende dem |
| US5919760A (en) * | 1996-04-12 | 1999-07-06 | Intensive Narcotic Detoxification Centers Of America, Llc | Method for treating acute and severe diarrhea |
| US6156771A (en) * | 1997-08-28 | 2000-12-05 | Rubin; Walter | Method for alleviation of lower gastrointestinal disorders in a human patient |
| GB9721139D0 (en) * | 1997-10-07 | 1997-12-03 | Glaxo Group Ltd | Medicaments |
-
2000
- 2000-11-20 TW TW089124545A patent/TWI263496B/zh not_active IP Right Cessation
- 2000-12-06 CO CO00093154A patent/CO5261535A1/es not_active Application Discontinuation
- 2000-12-07 PE PE2000001312A patent/PE20011030A1/es not_active Application Discontinuation
- 2000-12-07 AR ARP000106516A patent/AR026916A1/es unknown
- 2000-12-08 CN CNA2006100918377A patent/CN1875966A/zh active Pending
- 2000-12-08 MY MYPI20005769A patent/MY133423A/en unknown
- 2000-12-08 CZ CZ20021967A patent/CZ300690B6/cs not_active IP Right Cessation
- 2000-12-08 RU RU2002118316/15A patent/RU2264215C2/ru not_active IP Right Cessation
- 2000-12-08 EP EP00989967A patent/EP1286668B1/en not_active Expired - Lifetime
- 2000-12-08 EP EP04020247A patent/EP1488788A1/en not_active Withdrawn
- 2000-12-08 NZ NZ531489A patent/NZ531489A/en unknown
- 2000-12-08 PT PT00989967T patent/PT1286668E/pt unknown
- 2000-12-08 SK SK806-2002A patent/SK8062002A3/sk unknown
- 2000-12-08 CN CNB008168814A patent/CN1310644C/zh not_active Expired - Fee Related
- 2000-12-08 WO PCT/EP2000/012420 patent/WO2001041748A2/en not_active Ceased
- 2000-12-08 HU HU0301122A patent/HUP0301122A3/hu unknown
- 2000-12-08 NZ NZ566800A patent/NZ566800A/en unknown
- 2000-12-08 KR KR1020027007332A patent/KR100765579B1/ko not_active Expired - Fee Related
- 2000-12-08 TR TR2004/02293T patent/TR200402293T2/xx unknown
- 2000-12-08 IL IL14949600A patent/IL149496A0/xx unknown
- 2000-12-08 BR BR0016275-2A patent/BR0016275A/pt not_active Application Discontinuation
- 2000-12-08 DE DE60019814T patent/DE60019814T2/de not_active Expired - Lifetime
- 2000-12-08 PL PL355663A patent/PL202201B1/pl not_active IP Right Cessation
- 2000-12-08 ES ES00989967T patent/ES2240229T3/es not_active Expired - Lifetime
- 2000-12-08 JP JP2001543093A patent/JP2003523324A/ja active Pending
- 2000-12-08 AT AT00989967T patent/ATE293971T1/de not_active IP Right Cessation
- 2000-12-08 CA CA002388959A patent/CA2388959A1/en not_active Abandoned
- 2000-12-08 AU AU26728/01A patent/AU778869B2/en not_active Ceased
- 2000-12-08 MX MXPA02005695A patent/MXPA02005695A/es active IP Right Grant
- 2000-12-08 DK DK00989967T patent/DK1286668T3/da active
- 2000-12-08 SG SG200404415-2A patent/SG152025A1/en unknown
-
2002
- 2002-05-06 IL IL149496A patent/IL149496A/en not_active IP Right Cessation
- 2002-06-05 ZA ZA200204493A patent/ZA200204493B/xx unknown
- 2002-06-06 NO NO20022680A patent/NO20022680L/no not_active Application Discontinuation
-
2004
- 2004-08-26 EP EP07122308A patent/EP1913944A1/en not_active Withdrawn
-
2005
- 2005-02-22 AU AU2005200797A patent/AU2005200797B2/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60019814T2 (de) | Pharmazeutische kombinationen enthaltend tegaserod und omeprazole und ihre verwendung zur behandlung gastrointestinaler krankheiten | |
| DE69514794T2 (de) | Sublinguale dosierungsformen enthaltend apomorphin zur verwendung bei der behandlung von erektiler dysfunktion | |
| DE3590035C2 (de) | Diphenhydramin enthaltende analgetische und anti-inflammatorische Mittel und Verfahren zu ihrer Verwendung | |
| DE69431568T2 (de) | Inhibierung der migration und proliferation glatter muskeln mit hydroxycarbazolverbindungen | |
| DE69610323T2 (de) | Sich schnell im munde auflösende zusammensetzungen für dopaminagonisten | |
| DE69713890T3 (de) | Pharmazeutische kombination enthaltend einen wirkstoff mit angiotensin-ii antagonistischer aktivität und einen wirkstoff der die insulin-sensitivität erhöht | |
| DE60022021T2 (de) | Zubereitungen enthaltend Apomorphin und Sildenafil und ihre Verwendung zur Behandlung von erektiler Dysfunktion | |
| DE69633016T2 (de) | Optisch reines (-) norcisaprid zur behandlung von krankheiten des verdauungstrakt | |
| EP1572181B1 (de) | Pharmazeutische zusammensetzung aus einem beta-3-adrenozeptor-agonisten und einem serotonin- und/oder norepinephrin-reuptake-inhibitor und deren verwendung zur behandlung von blasenfunktionsstoerungen | |
| DE69430232T2 (de) | Hemmung der Symptome des prämenstruellen Synchroms/dysphorische Erkrankungen der späten lutealen Phase | |
| DE69133348T3 (de) | Behandlung von nicht-entzündlichen darmerkrankungen | |
| DE60210760T2 (de) | Verwendung von nk-1-rezeptorantagonisten gegen benigne prostatahyperplasie | |
| KR100399808B1 (ko) | 위장관 운동성 기능이상으로 인한 질환을 치료하는데 이용할 수 있는 광학적으로 순수한 (+) 노르시사프라이드 및 이를 함유하는 조성물 | |
| DE3115086A1 (de) | "dextromethorphan enthaltende pharamzeutische zusammensetzung und die verwendung von dextromethorphan zur schmerzbekaempfung" | |
| DE69929703T2 (de) | Neue orale formulierungen für 5-ht4 agonisten oder antagonisten | |
| EP0752246A2 (de) | Kappa-Opiate für entzündliche Darmerkrankungen | |
| DE2823174A1 (de) | Arzneimittel fuer die prophylaktische behandlung postoperativer tiefer venenthrombose | |
| AT389226B (de) | Verfahren zur herstellung einer analgetischen und antiinflammatorischen pharmazeutischen zubereitung | |
| DE60011650T2 (de) | Synergistische kombination von nk1-rezeptor antagonisten und gaba analogen | |
| WO2009036906A1 (de) | Zusammensetzung mit wirkstoffkombination aus einem laxans und einem entschäumer zur behandlung von obstipation | |
| DE60204694T2 (de) | Kombinationstherapie zur behandlung von herzinsuffizienz | |
| DE69529819T2 (de) | Neue kombination eines betablockers mit einem lokalanästhetikum | |
| DE69522764T2 (de) | Verwendung vom einem Bicycloheptan-Derivat | |
| EP0624373B1 (de) | Festes bismut- und amoxycillinhaltiges Arzneipräparat und seine Verwendung | |
| DD242749A5 (de) | Verbesserte entzuendungshemmende zusammensetzungen und verfahren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8328 | Change in the person/name/address of the agent |
Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336 |